11 New Telehealth Services Will Be Payable By CMS During Pandemic, Agency Says

Reimbursements will be available via telemedicine for neurostimulator analysis and cardiac rehabilitation, among other services

The US Medicare agency will allow reimbursements for a bevy of new telemedicine services during the COVID-19 public health emergency, it announced on 14 October.

Young female doctor consulting with elderly woman over video help line virtual medical appointment,GP prescribing medication to senior patient, telemedicine diagnosis, therapy and treatment concept
The CMS will pay for 11 additional telehealth services during the pandemic

The US Centers for Medicare and Medicaid Services is increasing the number of telehealth services it will reimburse by 11 new services, the agency announced on 14 October. Among the new categories of services the CMS will cover are neurostimulator analysis and programming, and cardiac and pulmonary rehabilitation.

Among the 11 services the agency will now reimburse are telemedicine services for intensive cardiac rehabilitation with exercise (payment code G0422), pulmonary rehabilitation with exercise (G0424) and analysis of neurostimulator devices without programming (95970), according to an

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

FDA Announces Classifications On 8 Device Types

 
• By 

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

State And International Enforcement Agencies May Step Up Amid Uncertain Federal Environment

 
• By 

States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.

More from Medtech Insight

FDA Announces Classifications On 8 Device Types

 
• By 

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

State And International Enforcement Agencies May Step Up Amid Uncertain Federal Environment

 
• By 

States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.